L. Gouw

发表

SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions

S. Tripp, L. Ramdas, R. Benjamin, 2017, PloS one.

Sarcoma Immunotherapy

Kevin B. Jones, R. Randall, Sunil Sharma, 2011, Cancers.

Sodium channel mutations in paramyotonia congenita and hyperkalemic periodic paralysis

M. Leppert, J. Mendell, M. Robertson, 1993, Annals of neurology.

Analysis of the dynamic mutation in the SCA7 gene shows marked parental effects on CAG repeat transmission.

S. Pulst, K. Fischbeck, S. Perlman, 1998, Human molecular genetics.

Retinal degeneration characterizes a spinocerebellar ataxia mapping to chromosome 3p

M. Leppert, H. Zoghbi, K. Digre, 1995, Nature Genetics.

Autosomal dominant cerebellar ataxia with retinal degeneration

K. Digre, J. Haines, L. Ptáček, 1994, Neurology.

Phase Ib study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma (ASTS).

J. Blay, A. Cesne, A. Italiano, 2013 .

Exploiting antitumor immunity to overcome relapse and improve remission duration

A. Lazar, Haesun Choi, P. Lin, 2011, Cancer Immunology, Immunotherapy.

Is There a Predisposition Gene for Ewing's Sarcoma?

L. Cannon-Albright, J. Schiffman, S. Lessnick, 2010, Journal of oncology.

Combining targeted therapy with immunotherapy (interferon-α): Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies.

M. Sabripour, R. Benjamin, Lei L Chen, 2013, Oncoimmunology.

Expression of the Rho‐family GTPase gene RHOF in lymphocyte subsets and malignant lymphomas

K. Elenitoba-Johnson, M. Lim, S. D. Jenson, 2005, British journal of haematology.

Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS).

J. Blay, G. Demetri, A. Italiano, 2013 .

Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation

Sunil Sharma, Sumati Gupta, K. Boucher, 2016, Investigational New Drugs.

Combining targeted therapy with immunotherapy (interferon-α)

M. Sabripour, R. Benjamin, Lei L Chen, 2012, Oncoimmunology.

Combination of targeted therapy (imatinib) with immunotherapy (peginterferon {alpha}-2b) to overcome drug resistance and tumor stem cells in gastrointestinal stromal tumors (GIST).

R. Benjamin, R. Randall, J. Trent, 2010 .

Proteolytic Cleavage of Ataxin-7 by Caspase-7 Modulates Cellular Toxicity and Transcriptional Dysregulation*

L. Ellerby, D. Bredesen, Jessica E. Young, 2007, Journal of Biological Chemistry.

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study

R. Kurzrock, Sunil Sharma, D. Hong, 2014, Investigational New Drugs.

Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies.

R. Kurzrock, D. Hong, H. Fingert, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.